Drug profile

The FDA adverse-event record for Glucosamine Supplement

104 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Glucosamine Supplement. See the species affected, top reactions, and outcomes below.

104
adverse-event reports
11.5%
death-coded share
Dog
most-reported species
26
Other abnormal test result NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
104
Total Reports
12
Deaths Reported
11.5%
Death Rate

Active Ingredients

Glucosamine Supplement

Administration Routes

OralUnknown

Species Affected

Dog 101
Cat 3

Most Affected Breeds

Retriever - Labrador 22
Shepherd Dog - German 15
Retriever - Golden 10
Dog (other) 4
Boxer (German Boxer) 3
Sheepdog - Shetland 3
Terrier - Bull - American Pit 2
Doberman Pinscher 2
Domestic Shorthair 2
Terrier - Jack Russell 2

Most Reported Reactions

Other abnormal test result NOS 26
Lethargy (see also Central nervous system depression in 'Neurological') 19
Vomiting 14
Diarrhoea 13
Decreased appetite 9
Weight loss 9
Emesis (multiple) 8
Anaemia NOS 8
Lack of efficacy - NOS 8
Polydipsia 7
Emesis 7
Abnormal radiograph finding 7

Outcome Breakdown

Ongoing
41 (39.4%)
Recovered/Normal
30 (28.8%)
Outcome Unknown
20 (19.2%)
Died
6 (5.8%)
Euthanized
6 (5.8%)
Recovered with Sequela
1 (1.0%)

Glucosamine Supplement Adverse Event Insights

104 reports name Glucosamine Supplement; 12 recorded a death outcome (11.5% of reported events, not a population-level mortality rate). Active ingredient: Glucosamine Supplement. Administration routes: Oral, Unknown.

By species: Dog (101 reports), Cat (3 reports). By breed: Retriever - Labrador (22), Shepherd Dog - German (15), Retriever - Golden (10).

Leading clinical signs: Other abnormal test result NOS (26), Lethargy (see also Central nervous system depression in 'Neurological') (19), Vomiting (14), Diarrhoea (13). Outcome, 104 coded reports: Ongoing leads at 39.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.